A Phase 1/2 interventional study of AZD0120 and Cyclophosphamide in Lupus Erythematosus, Systemic, sponsored by AstraZeneca. Recruiting at 20 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Lupus Erythematosus, Systemic by AstraZeneca — 19 open to participants now, 25 under way, 6 of them phase 3. Lupus Erythematosus, Systemic · AstraZeneca.
Among the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca, this one is the 12th largest by planned enrollment of the 26 interventional ones that give a count, is one of 9 that started in 2025, is one of 2 in phase 1/2, reaches primary completion later than 15 of the 24 other live ones, and was the 33rd registered.
1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →19 of the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Australia, Belgium, Chile and 7 more countries
Ages 5–17
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 5–80
AstraZeneca · Sites in China
Ages 18–70
AstraZeneca · Sites in United States
Ages 18–130 · Women only
AstraZeneca · Sites in United States, Canada, France and 6 more countries
Ages 18–70
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 11 · Phase 3 9 · Phase 4 1
First in 2008; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 52 across 879 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 109 across the 26 interventional studies, 500 across the 19 observational. Of the 20 that completed or were terminated, 11 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
5 of the studies in Lupus Erythematosus, Systemic by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT06530849Gracell Biotechnologies (Shanghai) Co., Ltd.A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus | 2027-02-01 |
| NCT05141201AstraZenecaSAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS) | 2027-03-31 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
| NCT06594068AstraZenecaProspective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.
The study will enrol adult participants with refractory Systemic Lupus Erythematosus (SLE) The study will be run in 2 parts;
First part is Phase 1b during which the study aims to assess safety and tolerability of AZD0120 in patients in refractory SLE cohorts
Second part is Phase 2, during which the study aims to assess safety, tolerability and efficacy of the selected dose, following Phase 1b completion, in patients with refractory SLE
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EXCLUSION:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of AZD0120
Biological: AZD0120 · Drug: Cyclophosphamide · Drug: Fludarabine
Single infusion of AZD0120 on visit DAY 1 after completing required lymphodepleting chemotherapy..
Also known as: GC012F
Lymphodepletion - specified dose prior to receiving AZD0120
Lymphodepletion - specified dose prior to receiving AZD0120
PHASE 1B: To evaluate the safety and tolerability of AZD0120 in participants with refractory systemic lupus erythematosus (SLE)
The incidence and severity of adverse events (AEs)
Time frame: 2 years
PHASE 1B: Recommended Phase 2 Dose (RP2D) of AZD0120 in for Phase 2
To determine the recommended phase 2 dose (RP2D) of AZD0120
Time frame: 2 years
PHASE 2: To evaluate the efficacy of AZD0120 in participants with refractory SLE
Proportion of participants achieving SRI-4 response
Time frame: 2 years
PHASE 1B & 2: To evaluate the efficacy of AZD0120 in participants with refractory SLE
Proportion of participants achieving SLE Responder Index 4 (SRI-4) response over time
Time frame: 2 years
PHASE 1B & 2: To evaluate the efficacy of AZD0120 in participants with refractory SLE
Proportion of participants achieving remission in SLE (DORIS) remission over time
Time frame: 2 years
PHASE 1B & 2: To evaluate the efficacy of AZD0120 in participants with refractory SLE
Proportion of participants achieving Lupus Low Disease Activity State (LLDAS) over time
Time frame: 2 years
PHASE 1B & 2: To evaluate the efficacy of AZD0120 in participants with refractory SLE
Proportion of participants achieving British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response over time
Time frame: 2 years
PHASE 1B & 2: To evaluate the efficacy of AZD0120 in participants with refractory SLE
Time from AZD0120 infusion and time from response to first disease flare
Time frame: 2 years
PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE
The area under the concentration-time curve (AUC) from time zero (T0) to the last measurable concentration time point (AUClast)
Time frame: 2 years
PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE
Area under the blood concentration-time curve from time zero to 28 days after dosing (AUC(0-28D))
Time frame: 2 years
PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE
The last measurable concentration of AZD0120 (Clast)
Time frame: 2 years
PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE
Maximum observed blood concentration (Cmax)
Time frame: 2 years
PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE
Terminal half-life of a drug during its elimination phase in pharmacokinetics (t1/2λz)
Time frame: 2 years
PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE
Time of the last measurable (quantifiable) concentration of a AZD0120 (Tlast)
Time frame: 2 years
PHASE 1B & 2: To characterize the cellular kinetics of AZD0120 in participants with refractory SLE
Time of maximum observed blood concentration (Tmax)
Time frame: 2 years
PHASE 1B & 2: To assess immunogenicity of AZD0120
Presence of AZD0120 antibodies
Time frame: 2 years
PHASE 1B & 2: To determine whether replication-competent lentivirus is present in participants that receive AZD0120
Presence of replication-competent lentivirus (RCL)
Time frame: 2 years
PHASE 2: To further characterize the safety of AZD0120 in participants with refractory SLE
Further characterization of the safety of AZD0120 by measuring the incidence and severity of Treatment Emergent Adverse Events (TEAEs)
Time frame: 2 years
PHASE 2: To assess changes from baseline for reported health-related quality of life, overall health status
To assess changes from baseline for Changes in Lupus Quality of life (LupusQoL)
Time frame: 2 years
PHASE 2: To assess changes from baseline for reported health-related quality of life, overall health status
To assess changes from baseline for FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY (FACIT)
Time frame: 2 years
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Started Apr 2025 (actual). Primary completion is estimated for May 2029, 48 months after the start.
Of 38 phase 1/2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's planned 48 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F
Lupus Erythematosus, Systemic →